Please login to the form below

Not currently logged in
Email:
Password:

Ardelyx appoints William Bertrand Jr to board of directors

Executive VP of Infinity Pharmaceuticals joins the team
Ardelyx

Ardelyx has appointed William Bertrand Jr to its board of directors.

Ardelyx is a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases.

Bertrand is currently executive VP of general counsel for Infinity Pharmaceuticals and prior to this he served as senior VP and CEO for Salix Pharmaceuticals.

He said: “Ardelyx is uniquely positioned within the life sciences, both in terms of the strength and track record of its senior team, as well as its strategy addressing diseases with substantial unmet needs.”

Mike Raab, president and CEO of Ardelyx, added: “Bill brings extensive experience helping companies growth through early stages of development and into commercialisation.

“His expertise, both operationally and as general counsel, will be of great importance as we continue to accelerate the advancement of our lead programs and develop into a commercial-ready company.”

27th October 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics